Limeng Chen

机构：Shenyang Pharmaceutical University, Chinese Academy of Medical Sciences & Peking Union Medical College, Peking Union Medical College Hospital, Translational Research in Oncology, Dian Diagnostics (China), Xiamen Tobacco Industry (China) · ORCID：0000-0002-8425-5742

发表论文 281 篇 · 总被引 3986 次 · h-index 33

代表论文

• Endothelial Vasoactive Pathways and Renal Outcomes: A Drug-Target Mendelian Randomization and Transcriptome-Wide Association Study (2025 · Kidney Diseases · 被引 2)
• Sorafenib (SOR)/simvastatin (SIM) dual-drug self-assembled nanoparticles for synergistic induction of tumor ferroptosis (2025 · Journal of Colloid and Interface Science · 被引 2)
• Copper-doxorubicin nanodot-based dual catalytic metal prodrug liposome for enhanced chemotherapy and Chemodynamic Combination Therapychemodynamic combination therapy (2025 · Nano Today · 被引 1)
• A multidisciplinary management model for severe gestational hypertriglyceridemia: using plasmapheresis to prevent pancreatitis in pregnancy (2025 · BMC Pregnancy and Childbirth · 被引 1)
• Viral bionic mangiferin nanosilicon system for overcoming multiple gastrointestinal barriers (2026 · Chemical Engineering Journal)
• Epidemiological and clinical characteristics of hospitalized patients with cardiomyopathies in China: a nationwide retrospective analysis (2026 · BMC Public Health)